Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments

Major limitations of current melanoma treatments are for instances of relapse and the lack of therapeutic options for BRAF wild-type patients who do not respond to immunotherapy. Many studies therefore focus on killing resistant subpopulations, such as Melanoma Initiating Cells (MICs) to prevent rel...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Mukherjee, Nabanita, Almeida, Adam, Partyka, Katie A., Lu, Yan, Schwan, Josianna V., Lambert, Karoline, Rogers, Madison, Robinson, William A, Robinson, Steven E, Applegate, Allison J, Amato, Carol M, Luo, Yuchun, Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356684/
https://ncbi.nlm.nih.gov/pubmed/27829238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13141
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky